Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

When a Number Is Just a Number: Duffy-Null Blood Group Phenotype, Absolute Neutrophil Count, and Incidence of Neutropenic Fever and Chemotherapy Dose Reductions in Patients Treated for Plasma Cell Dyscrasias

Maya Abdallah, Frances Arters, Jasmine Patel, Matthew Lefebvre, Camille V. Edwards, Adam Lerner, Fabio Petrocca, Vaishali Sanchorawala, Andrew Staron, John Mark Sloan, Raphael E Szalat

Blood (2023) 142 (Supplement 1): 7432.

https://doi.org/10.1182/blood-2023-187811

Published: 2023

Journal Articles

Incidence of Typical Neutrophil Count with Fy(a-b-) Status Among Hematology Referrals for Neutropenia at an Urban Safety-Net Hospital

Anya Parekh, Adam Lerner, Reggie Thomasson, John Mark Sloan

Blood (2022) 140 (Supplement 1): 1217–1218.

https://doi.org/10.1182/blood-2022-157152

Published: 2022

Journal Articles

Successful Conversion and Implementation to Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

David Hughes, Lynnette Henshaw, Frances Blevins, Camille V Edwards, Adam Lerner, John Mark Sloan, Vaishali Sanchorawala

Blood (2021) 138 (Supplement 1): 1975.

https://doi.org/10.1182/blood-2021-147518

Published: 2021

Journal Articles

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

Charles J. Milrod, Frances Blevins, David Hughes, Adam Lerner, Shayna Sarosiek, Vaishali Sanchorawala, J. Mark Sloan

Blood (2021) 137 (21): 2987–2989.

https://doi.org/10.1182/blood.2021010853

Published: 2021

Includes: Supplemental data

Journal Articles

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications

Frances Blevins, PA-C, David Hughes, PharmD, Charles Milrod, MD, Preya Patel, MD, Shayna DeMari, BA, Adam Lerner, MD, Shayna Sarosiek, MD, Vaishali Sanchorawala, MD, John Mark Sloan, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136775

Published: 2020

Journal Articles

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

David Hughes, PharmD, Radhika Jhaveri, PharmD, Bhavesh Shah, RPh, Frances Blevins, PA-C, Alexamil Rodriguez, CPhT, Shayna Sarosiek, MD, Adam Lerner, MD, John Mark Sloan, MD, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-135992

Published: 2020

Journal Articles

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

David Hughes, PharmD, Frances Blevins, PA-C, Bhavesh Shah, RPh, Shayna Sarosiek, Adam Lerner, MD, John Mark Sloan, MD

Blood (2019) 134 (Supplement_1): 4912.

https://doi.org/10.1182/blood-2019-124740

Published: 2019

Journal Articles

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Youn H. Kim, MD, Martine Bagot, MD PhD, Pier Luigi Zinzani, MD PhD, Madeleine Duvic, MD, Stephen Morris, MBBS, MRCP, FRCR, Ellen Kim, MD, Amy Musiek, MD, Pablo L. Ortiz-Romero, MD PhD, Craig Elmets, MD, Herbert A. Eradat, MDMS, Nina Magnolo, MD, Julia Scarisbrick, MD, Stéphane Dalle, MD PhD, David C. Fisher, MD PhD, Michi Shinohara, MD, Brian Poligone, MD PhD, Barbara Pro, MD, Pietro Quaglino, MD, Nishitha Reddy, MD MSCI, Brigitte Dreno, MD, Larisa J Geskin, MD, Ahmad S Halwani, MD, Amit Khot, MD, Marie Beylot-Barry, MD PhD, Neil Korman, MD, Frederick Lansigan, MD, Steven M. Horwitz, MD, Zanetta S. Lamar, MD, Alison J. Moskowitz, MD, Jillian Wells, MD, Oleg E. Akilov, MD PhD, Dolores Caballero, MD PhD, Richard Cowan, MBBS, MD MRCP, FRCR, Reinhard Dummer, MD, Mary Jo Lechowicz, MD, Francine M. Foss, MD, Lars Iversen, MD, Tomomitsu Miyagaki, MD PhD, Ryan Wilcox, MD, Pierluigi Porcu, MD, Maarten Vermeer, MD PhD, Sunil Abhyankar, MD, Yukihiko Kato, MD PhD, Theresa Pacheco, MD, Shigetoshi Sano, MD PhD, Basem M. William, MRCP,MD, Timothy S. Fenske, MD, Noriko Fukuhara, MD PhD, Koji Habe, MD PhD, Toshihisa Hamada, MD PhD, Eiji Kiyohara, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Adam Lerner, MD, Lawrence Mark, MD PhD, Javier Munoz, MD, Hiroyuki Okamoto, MD PhD, Christiane Querfeld, MD PhD, Jiro Uehara, MD, Hisashi Uhara, MD PhD, Kentaro Yonekura, MD PhD, Auris Huen, MD, Kensei Tobinai, MD PhD, Yoshiki Tokura, MD PhD, Erin Boh, MD PhD, Jan Nicolay, MD, Hidefumi Wada, MD, Mollie Leoni, MD, Takahiro Ito, MSc, Fiona Herr, PhD, Lubomir Sokol, MD PhD

Blood (2019) 134 (Supplement_1): 5300.

https://doi.org/10.1182/blood-2019-122778

Published: 2019

Journal Articles

Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact

Radhika Jhaveri, PharmD, Vaishali Sanchorawala, MD, John Mark Sloan, MD, Adam Lerner, MD, Shayna Sarosiek, Bhavesh Shah, RPh

Blood (2019) 134 (Supplement_1): 4758.

https://doi.org/10.1182/blood-2019-128992

Published: 2019

Journal Articles

Treatment Disparities in Minority Groups with Multiple Myeloma at a Large Safety-Net Hospital

Michael Dennis, MD, Diana Cirstea, MD, Asaf Maoz, MD, Adam Lerner, MD, Ami K. Patel, MD, Shayna Sarosiek, MD

Blood (2018) 132 (Supplement 1): 4864.

https://doi.org/10.1182/blood-2018-99-118472

Published: 2018

Journal Articles

Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study

Madeleine Duvic, MD, Youn H Kim, MD, Alain H Rook, MD, Adam Lerner, MD, Tadeusz Robak, MD, Alexey Samtsov, MD PhD, William McCulloch, M.B., FRCO, FFPM, Joel Waksman, PhD, Sean Whittaker

Blood (2014) 124 (21): 4451.

https://doi.org/10.1182/blood.V124.21.4451.4451

Published: 2014

Journal Articles

PDE4 Inhibitors Block TLR7 and TLR9-Driven Signaling, Proliferation and Cytokine Secretion in CLL Cells As Well As Proliferation Driven by Exposure to Apoptotic Cells

Ying Tan, M.D., Ph.D., Amanda A. Watkins, Ian R. Rifkin, M.D., Ph.D., Adam Lerner, MD

Blood (2012) 120 (21): 1774.

https://doi.org/10.1182/blood.V120.21.1774.1774

Published: 2012

Journal Articles

PDE4 Inhibitors Enhance DNA Damage-Induced Apoptosis In CLL

John Meyers, PhD, Adam Lerner, MD

Blood (2010) 116 (21): 2902.

https://doi.org/10.1182/blood.V116.21.2902.2902

Published: 2010

Journal Articles

Short-Term Exposure to Arginine Butyrate, in Combination with Ganciclovir, Is as Effective as Continuous Exposure for Virus-Targeted Therapy of EBV-Positive Lymphomas.

Douglas V Faller, MD, PhD, Sajal Ghosh, PhD, Tatyana Feldman, MD, Adam Lerner, MD, Judith Smith, RN, Andre Goy, MD, Ronald Berenson, MD, Susan Perrine, MD

Blood (2009) 114 (22): 4754.

https://doi.org/10.1182/blood.V114.22.4754.4754

Published: 2009

Journal Articles

Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.

Youn H Kim, MD, Marie-France Demierre, MD, Ellen J Kim, MD, Alain H Rook, MD, Adam Lerner, MD, Madeleine Duvic, MD, Sunil Reddy, MD, Tadeusz Robak, MD, PhD, Jürgen C Becker, MD, Alexey Samtsov, MD, William McCulloch, MB, FRCP, Sean Whittaker, MD, FRCP

Blood (2009) 114 (22): 2683.

https://doi.org/10.1182/blood.V114.22.2683.2683

Published: 2009

Journal Articles

Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.

Brad Pohlman, Ranjana Advani, MD, Madeleine Duvic, MD, Kenneth B. Hymes, MD, Tanin Intragumtornchai, MD, Arnuparp Lekhakula, Ofer Shpilberg, Adam Lerner, MD, Dina Ben-Yehuda, Marie beylot-Barry, Uwe Hillen, Jan Fagerberg, Francine M Foss

Blood (2009) 114 (22): 920.

https://doi.org/10.1182/blood.V114.22.920.920

Published: 2009

Journal Articles

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Youn Kim, MD, Sean Whittaker, MD, FRCP, Marie France Demierre, MD, Alain H Rook, MD, Adam Lerner, MD, Madeleine Duvic, MD, Sunil Reddy, MD, Ellen J Kim, MD, Tadeusz Robak, MD, Jürgen C Becker, MD, Alexey Samtsov, MD, William McCulloch, MB, FRCP, Archibald G Prentice, MBChB, FRCP, FRCPath

Blood (2008) 112 (11): 263.

https://doi.org/10.1182/blood.V112.11.263.263

Published: 2008

Journal Articles

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

Youn H. Kim, MD, Sunil Reddy, MD, Ellen J. Kim, MD, Alain H. Rook, MD, Adam Lerner, MD, Mariefrance Demierre, MD, Madeleine Duvic, MD, Sean Whittaker, MD, FRCP, Tadeusz Robak, MD, Jurgen C. Becker, MD, William McCulloch, MB, FRCP, Archibald G. Prentice, MB, FRCP, FRCPath, on behalf of All Investigators

Blood (2007) 110 (11): 123.

https://doi.org/10.1182/blood.V110.11.123.123

Published: 2007

Journal Articles

PDE4 Inhibitors Augment Glucocorticoid Receptor Levels in B-CLL Cells but Not in T Cells, B Cells, Monocytes or Neutrophils.

Adam Lerner, MD, John A. Meyers, BA, Josephine A. Taverna, MD, Anthony Makkinje, PhD

Blood (2006) 108 (11): 2608.

https://doi.org/10.1182/blood.V108.11.2608.2608

Published: 2006

Journal Articles

Zanolimumab, a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in Patients with CD4 + Mycosis Fungoides (MF) Type CTCL (Stage IB-IVB) Who Are Refractory or Intolerant to Targretin and One Other Standard Therapy.

Madeleine Duvic, MD, Youn Kim, M.D., Neil J. Korman, M.D., Erin Boh, M.D., Adam Lerner, M.D., Michael P. Heffernan, M.D., Kenneth B. Hymes, M.D., Theresa Pacheco, M.D., Craig A. Elmets, M.D., Steen Lisby, M.D., Ole Baadsgaard, M.D.

Blood (2006) 108 (11): 2731.

https://doi.org/10.1182/blood.V108.11.2731.2731

Published: 2006

NARROW

When a Number Is Just a Number: Duffy-Null Blood Group Phenotype, Absolute Neutrophil Count, and Incidence of Neutropenic Fever and Chemotherapy Dose Reductions in Patients Treated for Plasma Cell Dyscrasias

Incidence of Typical Neutrophil Count with Fy(a-b-) Status Among Hematology Referrals for Neutropenia at an Urban Safety-Net Hospital

Successful Conversion and Implementation to Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact

Treatment Disparities in Minority Groups with Multiple Myeloma at a Large Safety-Net Hospital

Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study

PDE4 Inhibitors Block TLR7 and TLR9-Driven Signaling, Proliferation and Cytokine Secretion in CLL Cells As Well As Proliferation Driven by Exposure to Apoptotic Cells

PDE4 Inhibitors Enhance DNA Damage-Induced Apoptosis In CLL

Short-Term Exposure to Arginine Butyrate, in Combination with Ganciclovir, Is as Effective as Continuous Exposure for Virus-Targeted Therapy of EBV-Positive Lymphomas.

Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.

Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study

Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.

PDE4 Inhibitors Augment Glucocorticoid Receptor Levels in B-CLL Cells but Not in T Cells, B Cells, Monocytes or Neutrophils.

Zanolimumab, a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in Patients with CD4 + Mycosis Fungoides (MF) Type CTCL (Stage IB-IVB) Who Are Refractory or Intolerant to Targretin and One Other Standard Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only